KR101276422B1 - Hiv 유입 억제제의 중합체-기재 조성물 및 콘쥬게이트 - Google Patents

Hiv 유입 억제제의 중합체-기재 조성물 및 콘쥬게이트 Download PDF

Info

Publication number
KR101276422B1
KR101276422B1 KR1020067019107A KR20067019107A KR101276422B1 KR 101276422 B1 KR101276422 B1 KR 101276422B1 KR 1020067019107 A KR1020067019107 A KR 1020067019107A KR 20067019107 A KR20067019107 A KR 20067019107A KR 101276422 B1 KR101276422 B1 KR 101276422B1
Authority
KR
South Korea
Prior art keywords
conjugate
polymer
delete delete
poly
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067019107A
Other languages
English (en)
Korean (ko)
Other versions
KR20060130225A (ko
Inventor
마이클 디 벤틀리
쉬안 자오
헤롤드 자페
Original Assignee
넥타르 테라퓨틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 넥타르 테라퓨틱스 filed Critical 넥타르 테라퓨틱스
Publication of KR20060130225A publication Critical patent/KR20060130225A/ko
Application granted granted Critical
Publication of KR101276422B1 publication Critical patent/KR101276422B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/12—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from polycarboxylic acids and polyhydroxy compounds
    • C08G63/46—Polyesters chemically modified by esterification
    • C08G63/48—Polyesters chemically modified by esterification by unsaturated higher fatty oils or their acids; by resin acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020067019107A 2004-03-15 2005-03-15 Hiv 유입 억제제의 중합체-기재 조성물 및 콘쥬게이트 Expired - Fee Related KR101276422B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55314604P 2004-03-15 2004-03-15
US60/553,146 2004-03-15
PCT/US2005/008632 WO2005089805A2 (en) 2004-03-15 2005-03-15 Polymer-based compositions and conjugates of hiv entry inhibitors

Publications (2)

Publication Number Publication Date
KR20060130225A KR20060130225A (ko) 2006-12-18
KR101276422B1 true KR101276422B1 (ko) 2013-06-19

Family

ID=34994420

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067019107A Expired - Fee Related KR101276422B1 (ko) 2004-03-15 2005-03-15 Hiv 유입 억제제의 중합체-기재 조성물 및 콘쥬게이트

Country Status (9)

Country Link
US (1) US9446139B2 (cg-RX-API-DMAC7.html)
EP (1) EP1725262B1 (cg-RX-API-DMAC7.html)
JP (1) JP4805911B2 (cg-RX-API-DMAC7.html)
KR (1) KR101276422B1 (cg-RX-API-DMAC7.html)
CN (1) CN101132812A (cg-RX-API-DMAC7.html)
AU (1) AU2005222641B2 (cg-RX-API-DMAC7.html)
CA (1) CA2558583C (cg-RX-API-DMAC7.html)
MX (1) MXPA06010505A (cg-RX-API-DMAC7.html)
WO (1) WO2005089805A2 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432331B2 (en) * 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
ATE444984T1 (de) * 2002-12-31 2009-10-15 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
RU2006128593A (ru) * 2004-01-07 2008-02-20 Тримерис, Инк. (Us) Синтетические пептиды, производные области hr2 белка gp41 вич, и их применение в терапии для ингибирования проникновения вируса иммунодефицита человека
DE102004031258A1 (de) * 2004-06-29 2006-02-09 Jennissen, Herbert P., Prof. Dr. Proteinhybride mit polyhydroxyaromatischen Aminosäure-Epitopen
US8273339B2 (en) 2005-04-12 2012-09-25 Nektar Therapeutics Polymer-based compositions and conjugates of antimicrobial agents
ATE537183T1 (de) 2006-02-02 2011-12-15 Trimeris Inc Hiv-fusionshemmerpeptide mit verbesserten biologischen eigenschaften
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
EP2319542B1 (en) 2006-02-21 2018-03-21 Nektar Therapeutics Segmented degradable polymers and conjugates made therefrom
WO2007140282A1 (en) * 2006-05-24 2007-12-06 Peg Biosciences Peg linker compounds and biologically active conjugates thereof
CN101534847A (zh) 2006-08-04 2009-09-16 普罗龙药品公司 修饰型促红细胞生成素
MX2009008549A (es) * 2007-02-09 2009-08-18 Enzon Pharmaceuticals Inc Tratamiento de canceres resistentes o refractarios con conjugados polimericos de brazos multiples de 7-etil-10-hidroxicamptotecina.
US20140011964A1 (en) 2007-02-28 2014-01-09 Serina Therapeutics, Inc. Activated Polyoxazolines and Conjugates and Compositions Comprising the Same
CN106046370A (zh) * 2007-02-28 2016-10-26 塞瑞纳治疗公司 聚噁唑啉poz化合物、合成其的方法、以及靶分子‑poz偶联物
CN101678125A (zh) * 2007-04-03 2010-03-24 特里梅里斯公司 用于递送抗病毒肽治疗剂的新制剂
CA2700354A1 (en) * 2007-09-25 2009-04-02 Trimeris, Inc. Novel methods of synthesis for therapeutic antiviral peptides
TW201010732A (en) * 2008-08-29 2010-03-16 Enzon Pharmaceuticals Inc Method of treating RAS associated cancer
US20100098654A1 (en) * 2008-10-21 2010-04-22 Fabio Pastorino Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
CA2780645C (en) * 2009-11-18 2018-01-16 Nektar Therapeutics Salt form of a multi-arm polymer-drug conjugate
WO2011084458A2 (en) * 2009-12-15 2011-07-14 The Johns Hopkins University Polymer-based compositions and methods for treatment of peritoneal disorders
US20110295365A1 (en) * 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
JP6226958B2 (ja) * 2012-04-18 2017-11-08 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドSiemens Healthcare Diagnostics Inc. コンジュゲート試薬を製造するための化合物および方法
CN104109240A (zh) * 2014-07-13 2014-10-22 成都市绿科华通科技有限公司 一种可作为药物载体的多孔聚乙二醇的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003723A1 (en) * 1999-07-09 2001-01-18 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US20010011115A1 (en) 1998-03-12 2001-08-02 J. Milton Harris Poly (ethylene glycol) derivatives with proximal reactive groups
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233480T2 (de) 1991-02-08 2006-01-05 Progenics Pharmaceuticals, Inc. CD4-gamma2- und CD4-IgG2-Chimären
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US20040228869A1 (en) 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US6469136B1 (en) 1999-07-07 2002-10-22 Trimeris, Inc. Methods and composition for peptide synthesis
US6541020B1 (en) 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
US6602498B2 (en) * 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
WO2001064710A2 (en) 2000-02-29 2001-09-07 Progenics Pharmaceuticals, Inc. Sulfated ccr5 peptides for hiv-1 infection
BR0312889A (pt) 2002-07-24 2005-06-14 Hoffmann La Roche Polipeptìdeo t20 peguilado
NZ537493A (en) 2002-07-24 2007-05-31 Hoffmann La Roche Pegylated T1249 polypeptide
CN100337689C (zh) * 2002-07-24 2007-09-19 弗·哈夫曼-拉罗切有限公司 聚亚烷基二醇酸加合物
JP4764630B2 (ja) * 2002-09-09 2011-09-07 ネクター セラピューティックス 水溶性ポリマーアルカナール
US7556813B2 (en) 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
WO2004060977A1 (en) 2002-12-30 2004-07-22 Nektar Therapeutics Al, Corporation Multi-arm polypeptide-poly(ethylene glycol) block copolymers as drug delivery vehicles
WO2004060967A1 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Methods for the formation of hydrogels using thiosulfonate compositions and uses thereof
KR101031206B1 (ko) * 2002-12-31 2011-04-27 넥타르 테라퓨틱스 말레암산 중합체 유도체 및 이의 바이오컨쥬게이트
US7910661B2 (en) 2003-01-06 2011-03-22 Nektar Therapeutics Thiol-selective water-soluble polymer derivatives
EP1596887B1 (en) * 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii moiety conjugates
PT2644206T (pt) 2003-05-23 2019-07-10 Nektar Therapeutics Derivados de peg contendo duas cadeias de peg
CA2556032A1 (en) * 2004-03-15 2005-09-29 Trimeris, Inc. Site-specific chemical modification of hiv gp41-derived peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010011115A1 (en) 1998-03-12 2001-08-02 J. Milton Harris Poly (ethylene glycol) derivatives with proximal reactive groups
WO2001003723A1 (en) * 1999-07-09 2001-01-18 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)

Also Published As

Publication number Publication date
EP1725262B1 (en) 2021-05-26
CA2558583C (en) 2013-07-09
CA2558583A1 (en) 2005-09-29
WO2005089805A3 (en) 2007-07-19
WO2005089805A2 (en) 2005-09-29
JP4805911B2 (ja) 2011-11-02
AU2005222641A1 (en) 2005-09-29
EP1725262A2 (en) 2006-11-29
MXPA06010505A (es) 2006-12-19
JP2007529539A (ja) 2007-10-25
KR20060130225A (ko) 2006-12-18
US20050226843A1 (en) 2005-10-13
AU2005222641B2 (en) 2011-04-07
CN101132812A (zh) 2008-02-27
US9446139B2 (en) 2016-09-20

Similar Documents

Publication Publication Date Title
JP4805911B2 (ja) Hiv侵入阻害剤のポリマー系組成物及び複合体
US20220143201A1 (en) Composition comprising a polymeric reagent
EP1885403B1 (en) Poly(ethyleneglycol) conjugates of Lysostaphin
AU2022268401A1 (en) Conjugates of an IL-2 moiety and a polymer
AU2016228555B2 (en) Conjugates of an IL-7 moiety and a polymer
CA2942571A1 (en) Conjugates of an il-15 moiety and a polymer
AU2004215912A1 (en) Polymer-factor VIII moiety conjugates
JP6626045B2 (ja) コリンエステラーゼ部分とポリマーとのコンジュゲート
US8905235B2 (en) Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom
JP7618383B2 (ja) オキシム含有リンケージを有する第viii因子部分のコンジュゲート

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20160330

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20170330

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20180329

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20190327

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20200324

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20210329

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20220325

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230613

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230613